Daily Cardiology Research Analysis
Three impactful cardiology studies stand out today: a large multicenter analysis refines arrhythmic risk in LMNA cardiomyopathy by variant type and location; a nationwide UNOS registry shows higher primary graft dysfunction after DCD heart transplant but similar early survival with timely ECMO; and a post-hoc HF analysis warns that loop diuretic down-titration in stable patients is frequently reversed and linked to short-term harm.
Summary
Three impactful cardiology studies stand out today: a large multicenter analysis refines arrhythmic risk in LMNA cardiomyopathy by variant type and location; a nationwide UNOS registry shows higher primary graft dysfunction after DCD heart transplant but similar early survival with timely ECMO; and a post-hoc HF analysis warns that loop diuretic down-titration in stable patients is frequently reversed and linked to short-term harm.
Research Themes
- Genotype–phenotype risk stratification in inherited cardiomyopathy
- Donor source and perioperative support strategies in heart transplantation
- Medication optimization and decongestion strategies in chronic heart failure
Selected Articles
1. Early Outcomes of Primary Graft Dysfunction Comparing Donation After Circulatory and Brain Death Heart Transplantation: An Analysis of the UNOS Registry.
In a UNOS registry study of 5017 first-time heart transplants, DCD grafts had higher PGD rates at 24 and 72 hours than DBD, yet 30-day survival among PGD cases was similar. DCD recipients more often required ECMO, and early ECMO was associated with lower PGD-related mortality.
Impact: This large, contemporary national analysis informs transplant program decisions on DCD utilization and supports proactive ECMO strategies to mitigate PGD mortality.
Clinical Implications: Centers can expand DCD utilization with structured PGD surveillance and protocols for early ECMO deployment without sacrificing early survival.
Key Findings
- Among 5,017 OHT recipients, DCD grafts (15.2%) had higher PGD at 24 h (7.9% vs 4.8%) and 72 h (5.9% vs 3.3%) than DBD.
- Despite higher PGD incidence, 30-day survival among PGD cases did not differ between DCD and DBD.
- ECMO use was more frequent in DCD and was associated with reduced PGD-related mortality at both 24 and 72 hours.
Methodological Strengths
- Nationwide contemporary registry with large sample size and standardized definitions of PGD
- Multivariable modeling and time-specific analyses (24 h, 72 h) with survival analyses
Limitations
- Observational design with potential residual confounding and center-level practice variability
- Short-term outcomes; long-term graft survival and quality metrics were not reported
Future Directions: Prospective studies to optimize PGD prevention bundles and ECMO initiation thresholds in DCD OHT, and evaluation of long-term outcomes and resource utilization.
BACKGROUND: Primary graft dysfunction (PGD) represents a leading cause of mortality in patients undergoing donation after brain death (DBD) orthotopic heart transplantation (OHT), requiring timely escalation to mechanical circulatory support. There is a lack of nationwide data regarding PGD after donation after circulatory death (DCD). Here, we evaluated the incidence and short-term outcomes of PGD following DCD. METHODS: Using the UNOS registry between 9/2023 and 9/2024, we identified all adult (≥18 years) recipients of OHT. The incidence and outcomes of moderate-severe PGD (24- and 72-h post-transplant) were compared between DCD and DBD. Predictors for mortality after PGD were analyzed using Cox proportional hazard models. 30-day survival was analyzed using the Kaplan-Meier method. RESULTS: A total of 5017 patients underwent first-time OHT, among whom 762 (15.2%) received DCD hearts. DCD had a significantly higher incidence of PGD at 24- (7.9% vs. 4.8%; p = 0.001) and 72-h (5.9% vs. 3.3%; p = 0.001) compared to DBD. 30-day (p = 0.3068) survival was not different between DCD and DBD patients with PGD. Similarly, for recipients with PGD at 72 h, 30-day (p = 0.327) survival was comparable. At 72 h, DCD recipients were more likely to be supported on ECMO (p = 0.016). Transplanting DCD organs did not impact PGD-associated mortality at 24- (HR 0.72, p = 0.442) and 72-h (HR 0.74, p = 0.457). Postoperative ECMO was associated with decreased risk of PGD-associated mortality in DCD recipients at 24- (p < 0.0001) and 72-h (p < 0.0001). CONCLUSIONS: While PGD rates appear higher in DCD, the associated mortality remains comparable to that of DBD. Early support on ECMO may confer survival benefits in DCD recipients with PGD.
2. Location of LMNA Variants and Clinical Outcomes in Cardiomyopathy.
In 718 LMNA cardiomyopathy patients, truncating variants conferred higher malignant ventricular arrhythmia risk, independent of position. Conversely, tail-domain missense variants and those in exons 7–12 were associated with lower arrhythmic and heart failure risks, refining genotype-based risk stratification.
Impact: Provides actionable, domain- and exon-specific risk modifiers for arrhythmic outcomes, guiding ICD decisions and family counseling in LMNA cardiomyopathy.
Clinical Implications: ICD consideration may be prioritized for truncating variant carriers, while selected tail-domain missense carriers may warrant nuanced surveillance strategies.
Key Findings
- Truncating LMNA variants increased malignant VA risk (HR 1.72) versus missense variants.
- Missense variants in the tail domain and exons 7–12 were associated with lower risk of malignant VA and advanced heart failure.
- Variant position did not modify risk among truncating variants, indicating type-driven risk for arrhythmia.
Methodological Strengths
- Large multicenter, international cohort with domain- and exon-level stratification
- Time-to-event analysis with multivariable adjustment for confounders
Limitations
- Retrospective design with potential genotype referral bias
- Functional mechanisms were inferential; no direct mechanistic experiments
Future Directions: Mechanistic studies to explain domain-specific effects and prospective validation for ICD risk algorithms incorporating variant type and location.
IMPORTANCE: Prior studies have suggested that patients with nonmissense (ie, truncating) variants causing LMNA cardiomyopathy have worse arrhythmic outcomes compared to those with missense variants. However, the effect of the spatial distribution of missense and truncating variants on clinical outcomes remains poorly understood. OBJECTIVE: To determine the association of the spatial distribution of missense and truncating LMNA variants with cardiac outcomes. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, retrospective, observational cohort study used data from an international registry (from January 2013 on) and data derived from tertiary cardiomyopathy centers (January 2000 and June 2017). Patients with likely pathogenic/pathogenic LMNA variants and no prior malignant ventricular arrhythmia (VA) were eligible for inclusion. Data analysis was completed from March 2022 to March 2025. MAIN OUTCOMES AND MEASURES: The primary outcome of time to VA was defined as sudden cardiac death, appropriate implantable cardioverter-defibrillator therapy, or other manifestations of hemodynamically unstable VA. The secondary composite outcome of advanced heart failure was defined as nonsudden cardiac death, implantation of a left ventricular assist device, or cardiac transplant. Outcomes were stratified by type of variant (missense or truncating), affected transcript position (head, rod, or tail), and location on the LMNA gene. RESULTS: A total of 718 patients were included, among whom mean (SD) age was 41.1 (14.3) years, 381 patients (53.1%) were female, and mean (SD) baseline left ventricular ejection fraction was 55.8% (13.3%). Over a median follow-up of 4.2 years, 223 patients experienced the primary outcome of malignant VA and 109 experienced the secondary outcome of advanced heart failure. Patients with truncating variants had a higher risk of VA (hazard ratio [HR], 1.72; 95% CI, 1.19-2.48; P = .004) but no difference in advanced heart failure (HR, 0.94; 95% CI, 0.64-1.40; P = .77) compared with patients with missense variants. There were no significant differences in the primary and secondary outcomes when stratifying truncating variants by location on the LMNA gene or transcript position. In contrast, on multivariable analysis, missense variants affecting the tail domain of LMNA (HR, 0.35; 95% CI, 0.16-0.78; P = .02) and located in exons 7 through 12 (HR, 0.39; 95% CI, 0.17-0.89; P = .035) were associated with a significantly lower risk of the primary outcome of malignant VA. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, truncating LMNA variants were associated with worse arrhythmic outcomes independent of variant position, whereas missense variants affecting the tail domain and located in exons 7 through 12 had better arrhythmic and heart failure outcomes. Understanding the mechanisms underlying these differences may have future therapeutic implications.
3. Exploring safety of down-titrating diuretics in heart failure management.
In a post-hoc TIME-CHF analysis (622 HF patients; 11,035 dose evaluations), loop diuretic down-titration was frequently reversed (30% within 30 days) and associated with higher 30-day hospitalization (3.4%) and mortality (2.0%), even after adjusting for congestion. Careful surveillance is warranted when reducing diuretics.
Impact: Challenges a common expert-opinion practice by quantifying short-term harms of diuretic down-titration, informing safer decongestion strategies.
Clinical Implications: Avoid routine down-titration without objective decongestion evidence; implement close follow-up within 30 days, patient education on early congestion signs, and ready access to rapid re-escalation pathways.
Key Findings
- Within 30 days of down-titration, 30.4% required re-increase of diuretic dose versus 8.0% when dose remained stable.
- Down-titration was associated with higher 30-day hospitalization (3.4% vs 1.0%) and mortality (2.0% vs 0.6%) compared with stable dosing (p<0.001).
- After adjusting for congestion level, down-titration doubled hospitalization risk and tripled death risk.
Methodological Strengths
- Granular, prospectively collected dosing data enabling 11,035 dose-change evaluations
- Adjustment for congestion level to mitigate confounding by disease status
Limitations
- Post-hoc observational analysis subject to residual confounding and indication bias
- Short-term (30-day) outcomes; not powered for long-term morbidity/mortality
Future Directions: Prospective trials to define safe down-titration criteria (biomarkers, imaging, weights) and remote monitoring pathways to prevent decompensation.
AIMS: Loop diuretics are widely used in heart failure (HF) for symptom relief. Guidelines advise treating patients with the lowest possible dose of loop diuretics to maintain euvolaemia, based on expert opinion only. However, data on the safety of this practice are scarce. This analysis aims to investigate the clinical course after changing loop diuretics in stable HF patients. METHODS AND RESULTS: A post-hoc analysis from the TIME-CHF study was conducted in 622 patients. Daily loop diuretic doses were meticulously recorded, resulting in 11 035 dose evaluations assessed. The frequency of relevant events within 30 days (hospitalization, death, dose change) following an up-titration, down-titration, or no change in diuretic therapy was calculated. Risk of hospitalization and deaths 30 days after down-titration was estimated after adjusting for congestion level. At baseline the cohort consisted mostly of males (59%), with a mean age of 77 years. Patients were highly symptomatic with 76% classified as New York Heart Association class III or IV. Within 30 days after a down-titration, diuretic dose necessitated an increase in 30.4% of cases, compared with 20.7% following up-titration and 8.0% on a stable dose. Hospitalization and death were significantly more frequent following down-titration (3.4% and 2% within 30 days, respectively) than with a stable dose (1% and 0.6%, p < 0.001). Similar hospitalization rates were observed after up-titration. The risk of hospitalization doubled and of death tripled after down-titration in patients with similar congestion levels. CONCLUSIONS: There is a significant risk that reduction in diuretic dose requires restart or increase of diuretics within a short period. Additionally, there may be a significant risk associated with diuretic dose reduction. Therefore, HF patients need to be closely monitored after down-titration of loop diuretic therapy.